References
- Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for Affibody molecules. J Mol Biol. 2010;398(2):232–247.
- Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584(12):2670–2680.
- Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med. 2010;51(6):892–897.
- Orlova A, Tran T, Widstrom C, et al. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med. 2007;20(3):397–404.
- Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868–876.
- Bhat AS, Rabuka D, Bleck G. The next step in homogenous bioconjugate development: optimizing payload placement and conjugate composition [Internet]. BioProcess International. 2014. [cited 2014 Oct 15]. http://www.bioprocessintl.com/manufacturing/antibody-non-antibody/next-step-homogenous-bioconjugate-development-optimizing-payload-placement-conjugate-composition/
- Strömberg P, Berglund MM, Ekholm C, et al. Development of Affibody® C5 inhibitors for versatile and efficient therapeutic targeting of the terminal complement pathway. Mol Immunol. 2014;61(2):256.
- Andersen JT, Pehrson R, Tolmachev V, et al. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem. 2011;286(7):5234–5241.
- Jonsson A, Dogan J, Herne N, et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008;21(8):515–527.
- Zurdo J, Arnell A, Obrezanova O, et al. Early implementation of QbD in biopharmaceutical development: a practical example. Biomed Res Int. 2015;2015:605427.
- Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–797.
- Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system Part II: role in immunity. Front Immunol. 6(257):2015.
- Owen EP, Wurzner R, Leisegang F, et al. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Mol Immunol. 2015;64(1):170–176.
- Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014;34(8):1016–1029.
- Risitano AM. Current and future pharmacologic complement inhibitors. Hematol Oncol Clin North Am. 2015;29(3):561–582.
- Howard JF Jr., Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84.
- Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13(1):70–83.
- Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015;14(12):857–877.
- Johnson CK, Leca N. Eculizumab use in kidney transplantation. Curr Opin Organ Transplant. 2015;20(6):643–651.
- Weber BH, Charbel Issa P, Pauly D, et al. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int. 2014;111(8):133–138.